O
RLMD icon

OrbiMed’s Relmada Therapeutics RLMD Stock Holding History

OrbiMed’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.1M Sell
3,631,195
-1,084,669
-23% -$7.58M 0.47% 57
2026
Q1 		$32.8M Buy
4,715,864
+2,105,264
+81% +$9.96M 0.65% 46
2025
Q4 		$12.6M Buy
+2,610,600
New +$8.75M 0.26% 76

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed's RLMD Position: Q2 2026 in Review

OrbiMed reduced its Relmada Therapeutics (RLMD) stake by 23% in Q2 2026, selling an estimated $7.58M and leaving 3,631,195 shares worth $25.1M. The position accounts for 0.47% of the portfolio, ranked #57.

OrbiMed first reported a position in RLMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $32.8M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • OrbiMed held 3,631,195 shares of Relmada Therapeutics worth $25.1M as of Q2 2026.
  • OrbiMed sold 1,084,669 Relmada Therapeutics shares in Q2 2026, an estimated $7.58M.
  • Relmada Therapeutics made up 0.47% of OrbiMed's portfolio in Q2 2026, its #57 holding.
  • OrbiMed first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • OrbiMed's Relmada Therapeutics position peaked at $32.8M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.